130 related articles for article (PubMed ID: 18617914)
21. [Gene therapy study on bladder cancer with recombinant adenoviral vector carrying LRIG1 gene driven by Survivin promoter].
Yan ZJ; Cheng Y; Jiang JH; Hu JS; Shi XD
Zhonghua Wai Ke Za Zhi; 2012 Aug; 50(8):732-6. PubMed ID: 23157908
[TBL] [Abstract][Full Text] [Related]
22. High expression of Notch ligand Jagged2 is associated with the metastasis and recurrence in urothelial carcinoma of bladder.
Li W; Liu M; Feng Y; Huang YF; Xu YF; Che JP; Wang GC; Zheng JH
Int J Clin Exp Pathol; 2013; 6(11):2430-40. PubMed ID: 24228105
[TBL] [Abstract][Full Text] [Related]
23. Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect.
Seol JY; Park KH; Hwang CI; Park WY; Yoo CG; Kim YW; Han SK; Shim YS; Lee CT
Cancer Gene Ther; 2003 Jul; 10(7):540-8. PubMed ID: 12833134
[TBL] [Abstract][Full Text] [Related]
24. Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment.
Qu XJ; Yang JL; Russell PJ; Goldstein D
J Urol; 2004 Aug; 172(2):733-8. PubMed ID: 15247772
[TBL] [Abstract][Full Text] [Related]
25. Conditioned medium from actinomycin D-treated apoptotic cells induces mitochondria-dependent apoptosis in bystander cells.
Jin C; Wu S; Lu X; Liu Q; Zhang L; Yang J; Xi Q; Cai Y
Toxicol Lett; 2012 May; 211(1):45-53. PubMed ID: 22421271
[TBL] [Abstract][Full Text] [Related]
26. Dual effects of radiation bystander signaling in urothelial cancer: purinergic-activation of apoptosis attenuates survival of urothelial cancer and normal urothelial cells.
Bill MA; Srivastava K; Breen C; Butterworth KT; McMahon SJ; Prise KM; McCloskey KD
Oncotarget; 2017 Nov; 8(57):97331-97343. PubMed ID: 29228614
[TBL] [Abstract][Full Text] [Related]
27. Impaired alpha-interferon signaling in transitional cell carcinoma: lack of p48 expression in 5637 cells.
Matin SF; Rackley RR; Sadhukhan PC; Kim MS; Novick AC; Bandyopadhyay SK
Cancer Res; 2001 Mar; 61(5):2261-6. PubMed ID: 11280796
[TBL] [Abstract][Full Text] [Related]
28. Adenovirus mediated alpha interferon (IFN-alpha) gene transfer into CD34+ cells and CML mononuclear cells.
Feldman E; Ahmed T; Lutton JD; Farley T; Tani K; Freund M; Asano S; Abraham NG
Stem Cells; 1997; 15(5):386-95. PubMed ID: 9323802
[TBL] [Abstract][Full Text] [Related]
29. The role of natural killer cells in adenovirus-mediated p53 gene therapy.
Carroll JL; Nielsen LL; Pruett SB; Mathis JM
Mol Cancer Ther; 2001 Nov; 1(1):49-60. PubMed ID: 12467238
[TBL] [Abstract][Full Text] [Related]
30. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer.
Yamashita M; Rosser CJ; Zhou JH; Zhang XQ; Connor RJ; Engler H; Maneval DC; Karashima T; Czerniak BA; Dinney CP; Benedict WF
Cancer Gene Ther; 2002 Aug; 9(8):687-91. PubMed ID: 12136430
[TBL] [Abstract][Full Text] [Related]
31. Adenovirus-mediated interferon alpha gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer.
Ohashi M; Yoshida K; Kushida M; Miura Y; Ohnami S; Ikarashi Y; Kitade Y; Yoshida T; Aoki K
Br J Cancer; 2005 Aug; 93(4):441-9. PubMed ID: 16106250
[TBL] [Abstract][Full Text] [Related]
32. Adenovirus-mediated gene therapy for bladder cancer: efficient gene delivery to normal and malignant human urothelial cells in vitro and ex vivo.
Chester JD; Kennedy W; Hall GD; Selby PJ; Knowles MA
Gene Ther; 2003 Jan; 10(2):172-9. PubMed ID: 12571646
[TBL] [Abstract][Full Text] [Related]
33. The ultrastructure of the noninvolved urothelium of tumor-bearing patients before and after interferon treatment.
Stravoravdi P; Belivanis J; Dimopoulos T; Hatzigiannis J; Polyzonis M
J Interferon Res; 1992 Dec; 12(6):397-402. PubMed ID: 1289406
[TBL] [Abstract][Full Text] [Related]
34. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
[TBL] [Abstract][Full Text] [Related]
35. Effect of TNF-alpha and IFN-alpha on the proliferation and cytotoxicity of lymphokine-activated killer cells in patients with bladder cancer.
Wang Z; Cheng Y; Zheng R; Qin D; Liu G
Chin Med J (Engl); 1997 Mar; 110(3):180-3. PubMed ID: 9594335
[TBL] [Abstract][Full Text] [Related]
36. Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder.
Carballido JA; Moltó LM; Manzano L; Olivier C; Salmerón OJ; Alvarez de Mon M
Cancer; 1993 Sep; 72(5):1743-8. PubMed ID: 8348503
[TBL] [Abstract][Full Text] [Related]
37. Organ and species specificity in the stimulation of transitional epithelial cell growth by fibroblasts.
Staack A; Alexander T; Merguerian P; Terris MK
Eur Urol; 2001 Apr; 39(4):471-7. PubMed ID: 11306889
[TBL] [Abstract][Full Text] [Related]
38. Nonviral cytokine gene therapy on an orthotopic bladder cancer model.
Wu Q; Mahendran R; Esuvaranathan K
Clin Cancer Res; 2003 Oct; 9(12):4522-8. PubMed ID: 14555526
[TBL] [Abstract][Full Text] [Related]
39. Cytokine-mediated antitumor effect of OK-432 on urinary bladder tumor cells in vitro.
Sakano S; Shimabukuro T; Ohmoto Y; Naito K
Urol Res; 1997; 25(4):239-45. PubMed ID: 9286031
[TBL] [Abstract][Full Text] [Related]
40. Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma.
Jiang Y; Zhong B; Kawamura K; Morinaga T; Shingyoji M; Sekine I; Tada Y; Tatsumi K; Shimada H; Hiroshima K; Tagawa M
BMC Cancer; 2016 Jul; 16():455. PubMed ID: 27405588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
